|
1
|
Liu J, Zhang J, Song K, Du J, Wang X, Liu J, Li B, Ouyang R, Miao Y, Sun Y, Li Y. Tumor Microenvironment Modulation Platform Based on Composite Biodegradable Bismuth-Manganese Radiosensitizer for Inhibiting Radioresistant Hypoxic Tumors. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2021; 17:e2101015. [PMID: 34263544 DOI: 10.1002/smll.202101015] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 05/08/2021] [Indexed: 05/21/2023]
Abstract
Solid tumors possess a unique internal environment with high-level thiols (mainly glutathione), over-expressed H2 O2 , and low oxygen partial pressure, which severely restrict the radiotherapy (RT) efficacy. To overcome the imperfections of RT alone, there is vital to design a multifunctional radiosensitizer that simultaneously achieves multimodal therapy and tumor microenvironment (TME) regulation. Bismuth (Bi)-based nanospheres are wrapped in the MnO2 layer to form core-shell-structured radiosensitizer (Bi@Mn) that can effectively load docetaxel (DTX). The solubility of Bi@Mn-DTX is further improved via folic acid-modified amphiphilic polyethylene glycol (PFA). Bi@Mn-DTX-PFA can specifically respond to the TME to realize multimodal therapy. Primarily, the outer MnO2 layer responds with H2 O2 and glutathione to release oxygen and generate •OH, thereby alleviating hypoxia and achieving chemodynamic therapy (CDT). Afterward, the strong coordination between Bi3+ and deprotonated thiol groups in glutathione allows the mesoporous Bi-containing core bonding with glutathione to form a water-soluble complex. These actions conduce Bi@Mn-DTX-PFA degradation, further releasing DTX to implement chemotherapy (CHT). In addition, the degradation in vivo and tumor enrichment of Bi@Mn-PFA are explored via T1 -weighted magnetic resonance and computed tomography imaging. The biodegradable composite Bi@Mn-DTX-PFA can simultaneously modulate the TME and achieve multimodal treatment (RT/CDT/CHT) for hypoxic tumors.
Collapse
Affiliation(s)
- Jie Liu
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Jing Zhang
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Kang Song
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Jun Du
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Xiang Wang
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Jinliang Liu
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Bing Li
- Department of Research and Development & Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, 201321, China
- Shanghai Key Laboratory of Radiation Oncology (20dz2261000), Shanghai, 201321, China
- Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, 201321, China
| | - Ruizhuo Ouyang
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Yuqing Miao
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| | - Yun Sun
- Department of Research and Development & Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, 201321, China
- Shanghai Key Laboratory of Radiation Oncology (20dz2261000), Shanghai, 201321, China
- Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, 201321, China
| | - Yuhao Li
- Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China
| |
Collapse
|